Avacta Group PLC

Receive alerts
Market Cap:
£24.39 m
52 weeks high
52 weeks low

Viewing results 1-8 of 8


Analysts eye more licensing deals for Avacta’s Affimer technology in 2019

Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences ...

on 2/5/19

Avacta - interim results confirm progress

Avacta Group PLC (LON:AVCT) reported interim results to January 2019, confirming good progress on key development programmes Lead immune checkpoint inhibitor programmes continue to move towards in-man clinical data in 2020 Major development partnership and......

on 9/4/19

Avacta Group - Exciting partnership with Bach BioSciences

Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Boston-based Bach BioSciences, to exploit the potential of the Affimer platform for the development of a novel class of drug conjugates. ...

on 30/7/18

Avacta Group - Rapid Progress of Immuno-oncology Programs

KEY INVESTOR MESSAGES Faster than expected development of the second immuno-oncology (I-O) program, a LAG3 inhibitor, allows company to evolve its lead program into a more ambitious LAG3/PD-L1 bispecific aiming to enter the clinic in 2020 Good progress of the ongoing external collaborations in two key areas:......

on 16/4/18

Avacta Group Plc - On track and undervalued

At the AGM of January 18th, Avacta reported good progress for both the Affimer therapeutic and reagents programs. Their lead immuno-oncology development program is proceeding according to plan and multiple development milestones are expected in the course of 2018 (see next section for further details). ...

on 24/1/18

Avacta Group - Capital Network: Preliminary Results

Avacta’s FY 2017 Preliminary Results: Reagents and therapeutics programs all on track KEY INVESTOR MESSAGES Avacta’s Affimer® technology is a proprietary alternative to antibodies with key technical and commercial benefits Avacta is building a pipeline of Affimer drugs for immuno-oncology and growing......

on 4/10/17

Avacta Group - Capital Network: Milestone Immunogenicity Data

On April 3rd Avacta (AVCT.LON) released the results of a pre-clinical study showing that Affimers have an immunogenicity profile comparable to widely used biotech drugs.  This leaves Avacta (AVCT.LON) on track to move their immuno-oncology therapeutic Affimer into the clinic by 2019. ...

on 5/4/17

Avacta Group - Capital Network: Initiation of Coverage

Avacta (AVCT.LON), a UK-based biotechnology company, has developed an innovative proteinscaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets. ...

on 8/3/17